1. Plasma microRNA-320, microRNA-let-7e and microRNA-21 as novel potential biomarkers for the detection of retinoblastoma
- Author
-
Yan‑Feng Sun, Qiu‑Ling Liu, Shan‑Shan Liu, Yan‑Shan Li, Li‑Xia Miao, Yu‑Shi Wang, Hong‑Yan Liu, and Jun Wang
- Subjects
Pathology ,medicine.medical_specialty ,Oncogene ,microRNA ,Retinoblastoma ,business.industry ,General Neuroscience ,Enolase ,Cancer ,General Medicine ,Articles ,Cell cycle ,medicine.disease ,Molecular medicine ,General Biochemistry, Genetics and Molecular Biology ,retinoblastoma ,Biomarker (cell) ,medicine ,Cancer research ,biomarker ,General Pharmacology, Toxicology and Pharmaceutics ,business ,plasma - Abstract
Retinoblastoma (RB) is a childhood malignancy caused by inactivation of the RB gene, with neuron-specific enolase (NSE) levels considered as its diagnostic marker. MicroRNAs (miRNAs) have been proven to play a significant role in multiple physiological and pathological processes and several miRNAs were identified as tumor biomarkers in recent studies. In the present study, 65 plasma samples were collected from RB patients and 65 samples from healthy individuals to serve as controls. The miRNA levels were measured via quantitative reverse transcription-polymerase chain reaction and their association with RB was assessed by statistical data analysis and receiver operating characteristic curves. Plasma miRNA (miR)-320, miR-let-7e and miR-21 levels were downregulated in the patient samples, the areas under the curves (AUCs) were 0.548–0.660, whereas the AUCs of combined classifiers were ≥0.990. The plasma miRNA levels, particularly of miR-320, were found to be of value in RB diagnosis and may be considered as novel diagnostic biomarkers.
- Published
- 2014